Compare PAHC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | MNKD |
|---|---|---|
| Founded | 1946 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2014 | 2004 |
| Metric | PAHC | MNKD |
|---|---|---|
| Price | $36.03 | $4.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $47.00 | $8.33 |
| AVG Volume (30 Days) | 174.1K | ★ 3.1M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 104.20 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $833,350,000.00 | $348,966,000.00 |
| Revenue This Year | $4.17 | $26.63 |
| Revenue Next Year | $3.30 | $14.81 |
| P/E Ratio | $49.15 | ★ N/A |
| Revenue Growth | 4.12 | ★ 22.23 |
| 52 Week Low | $28.25 | $2.23 |
| 52 Week High | $60.08 | $6.51 |
| Indicator | PAHC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 66.85 |
| Support Level | $32.97 | $3.77 |
| Resistance Level | $40.69 | $4.28 |
| Average True Range (ATR) | 1.65 | 0.19 |
| MACD | -0.36 | 0.08 |
| Stochastic Oscillator | 37.35 | 86.55 |
Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.